Biota Initiates Additional Clinical Trials of Laninamivir Octanoate Link here. ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-10-22 17:53:512018-01-06 17:54:07Avita Medical Annual Report to shareholders
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-10-22 17:40:552018-01-06 17:41:49Notice of Annual General Meeting and explanatory memorandum to shareholders
Pharmaxis announcement link here. Pharmaceutical company Pharmaxis today announced the retirement of two non‐executive directors, Dr John Villiger and Mr Richard van den Broek. Dr Villiger joined the Board in November 2006. His career in the global pharmaceutical industry as a founder of The Medicines Company Inc. brought considerable clinical, regulatory and entrepreneurial experience to the […]
Auckland, New Zealand, September 6th 2013 – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team following the Company’s successful US$3.6m financing earlier in 2013. Nexus6 is a global leader in the development and manufacturing of intelligent monitoring solutions that improve the management of COPD and […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-09-06 17:42:062018-01-06 17:42:29Nexus6 Steps Up its Global Presence with Three New Appointments
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-30 17:44:502018-01-06 17:45:08Avita Medical Appendix 4E Year Ending 30 June 2013
Alchemia Announcement link here. • Net profit share from fondaparinux of A$9.6m (US$9.5m) for the financial year • Annual loss for the year of A$4.8m, compared with A$15.1m for the previous year • Cash and receivables at 30 June 2013 of A$25.3m • Phase III trial of HA Irinotecan fully recruited • Collaboration with Merck Serono […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-30 17:44:172018-01-06 17:44:49Alchemia Announces Results For FY 2013 and Progress Across Its Major Assets
Pharmaxis press release link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment. Pharmaxis CEO Mr Gary Phillips said, “Negotiations with the French Healthcare […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-29 17:45:182018-01-06 17:45:40Pharmaxis Announces Delay to French Pricing for Bronchitol
Pharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-21 17:47:222018-01-06 17:47:54Australian Medical Media Release: Simplified PBS Listing for Bronchitol (Pharmaxis)
Biota Initiates Additional Clinical Trials of Laninamivir Octanoate
/in Portfolio CompaniesBiota Initiates Additional Clinical Trials of Laninamivir Octanoate Link here. ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a […]
Avita Medical Annual Report to shareholders
/in Avita Medical, Portfolio CompaniesFinancial report 2013 link here.
Notice of Annual General Meeting and explanatory memorandum to shareholders
/in Avita Medical, Portfolio CompaniesLink here. Date of Meeting: 22 November 2013 Time of Meeting: 2pm WST Place of meeting: Function Room, QV1, 250 St Georges Terrace, Perth, WA 6000
Alchemia Ltd Investor Presentation September 2013
/in Portfolio CompaniesLink to the investor presentation here.
19.09.2013 – Pharmaxis Announces Two Board Retirements
/in Destiny Pharma, Portfolio CompaniesPharmaxis announcement link here. Pharmaceutical company Pharmaxis today announced the retirement of two non‐executive directors, Dr John Villiger and Mr Richard van den Broek. Dr Villiger joined the Board in November 2006. His career in the global pharmaceutical industry as a founder of The Medicines Company Inc. brought considerable clinical, regulatory and entrepreneurial experience to the […]
Nexus6 Steps Up its Global Presence with Three New Appointments
/in Adherium, Portfolio CompaniesAuckland, New Zealand, September 6th 2013 – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team following the Company’s successful US$3.6m financing earlier in 2013. Nexus6 is a global leader in the development and manufacturing of intelligent monitoring solutions that improve the management of COPD and […]
Avita Medical Appendix 4E Year Ending 30 June 2013
/in Avita Medical, Portfolio CompaniesAvita Medical ASX announcement link here.
Alchemia Announces Results For FY 2013 and Progress Across Its Major Assets
/in Portfolio CompaniesAlchemia Announcement link here. • Net profit share from fondaparinux of A$9.6m (US$9.5m) for the financial year • Annual loss for the year of A$4.8m, compared with A$15.1m for the previous year • Cash and receivables at 30 June 2013 of A$25.3m • Phase III trial of HA Irinotecan fully recruited • Collaboration with Merck Serono […]
Pharmaxis Announces Delay to French Pricing for Bronchitol
/in Destiny Pharma, Portfolio CompaniesPharmaxis press release link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment. Pharmaxis CEO Mr Gary Phillips said, “Negotiations with the French Healthcare […]
Australian Medical Media Release: Simplified PBS Listing for Bronchitol (Pharmaxis)
/in Destiny Pharma, Portfolio CompaniesPharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]